Abstract Background The XEN45 Gel Stent is a subconjunctival filtering device that has
demonstrated promising efficacy. This meta-analysis quantitatively evaluates reported …

Abstract The XEN45 Gel Stent (Allergan Inc., Irvine, CA) allows the drainage of aqueous into
the sub-conjunctival space, through a minimally-invasive approach. This systematic review …

Objective To evaluate efficacy and safety outcomes of the Xen 45 gel stent implant over 24
months of follow-up. Methods A retrospective analysis of prospectively collected data from …

Purpose To compare the effectiveness of ab interno versus ab externo placement of XEN45
gel stents in patients with open-angle glaucoma. Design Single-center, noncontrolled …

Purpose: To evaluate 5-year outcomes of XEN 45 gel stent implantation (XEN) in patients
with open angle glaucoma. Methods: This is a prospective, single-center, interventional …

Abstract Purpose The XEN45 Gel Stent is currently the only FDA-approved sub-conjunctival
minimally invasive glaucoma surgery (MIGS) procedure. It has been used worldwide either …

Purpose To describe the efficacy and safety of open versus closed conjunctival implantation
of the XEN45 Gel Stent (Allergan Inc). Design Retrospective, multicenter study. Participants …

Objective To reliably compare the three-year clinical outcome and safety of XEN45 Gel Stent
implantation (XEN) vs. trabeculectomy (TRAB) in patients with glaucoma. Subject/methods …

Purpose To evaluate the 2-year treatment outcomes of the XEN gel stent (Allergan, Inc,
Irvine, CA) in glaucoma patients. Design Prospective, single-center interventional study …

Purpose: To report efficacy and safety measures of the XEN45 gel stent at 36 months in the
UK National Health Service setting. Methods: Retrospective non-comparative audit of the …